Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.

This study found that co-administering sasam-Kyeongokgo with gefitinib enhanced gefitinib's anti-tumor activity and exhibited favorable anti-cachexia effects in mice with non-small-cell lung cancer.

This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.